// App-Quantinova.ai

2793 : Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Researchers

Presenter

  • Andrew E. Place

Principal Investigators

  • Christopher J. Forlenza

  • Marion Gambart

  • Todd M. Cooper

  • Christopher Fraser

  • Gunnar Cario

  • Maureen M O'Brien

  • Nicolas U. Gerber

  • Phillip Barnette

  • Dirk Reinhardt

  • Giridharan Ramsingh

  • Bo Tong

  • Kristina Unnebrink

  • Deeksha Vishwamitra

  • Fengjiao Dunbar

  • Betty A. Prine

  • Tammy L. Palenski

  • Mignon L. Loh

Medical Centers

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • CHU de Toulouse-Purpan, Toulouse, France

  • Seattle Children's Cancer and Blood Disorders Center, Seattle, WA

  • Queensland Children’s Hospital, Brisbane, Australia

  • Universitatsklinikum Schleswig-Holstein, Kiel, Germany

  • Cincinnati Childrens Hospital Medical Center and University of Cincinnati, Cincinnati, OH

  • Children's Hospital Zurich, Zurich, Switzerland

  • Primary Childrens Hospital, Salt Lake City, UT

  • University of Duisburg-Essen, Essen, Germany

  • Genentech, Inc., South San Francisico, CA

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • UCSF Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Locations

  • United States

  • France

  • Australia

  • Germany

  • Switzerland

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Tumor lysis syndrome

Biomarkers

  • B-cell lymphoma 2

  • Breakpoint Cluster Region

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • I

Study Id's

  • NCT03236857

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved